The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD

Sponsor

Duk Lyul Na (Other)

Overall Status

Unknown status

CT.gov ID

NCT01696591

Collaborator

Medipost Co Ltd. (Industry)

Enrollment

Location

Duration (Months)

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to determine the long-term safety and exploratory efficacy of NEUROSTEM®-AD, administered via an open brain surgery to subjects with dementia of the Alzheimer's type, who were eligible for and enrolled in the earlier part of the phase I. Aside from the subjects who completed the earlier part of the Phase I, 3 additional subjects with comparable demographics and disease characteristics as the treatment group will be enrolled into a control group, followed-up for 3 months, and compared for various disease progression indicators with the treatment group.

The hypothesis is that NEUROSTEM®-AD is safe and effective in the treatment of dementia of the Alzheimer's type.

Condition or Disease	Intervention/Treatment	Phase
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders	Biological: NEUROSTEM®-AD

Detailed Description

This is a long-term follow up study of the earlier part of the phase I, during which the safe and effective dose(safety) of NEUROSTEM®-AD was determined for implantation into the brains of subjects with Dementia of the Alzheimer's type. Subjects with Dementia of the Alzheimer's type, who signed the informed consent form and meet the eligibility criteria, were implanted with a single dose of NEUROSTEM®-AD, hUBC-MSCs, into the brain. The subjects were hospitalized for 5 to 10 days following the surgical implantation and were observed for acute adverse events: Gradient echo MRI within the the 24 hours post-op, vital signs, clinical laboratory tests, chest x-rays within Day 2. On Day 14, DLT was assessed, and the subjects were followed up on the safety and disease progression of dementia (of the Alzheimer's type) for 12 weeks post-implantation.

In this part of the study, the subjects described above will be followed-up for upto Month 24, and 3 additional subjects with comparable demographics and disease characteristics as the treatment group (refer to Inclusion/Exclusion Criteria) will be enrolled as a control group, followed up for 3 months and compared with the treatment group for various indicators of the disease progression.

Study Design

Study Type:

Observational

Anticipated Enrollment :

14 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD

Study Start Date :

Mar 1, 2012

Anticipated Primary Completion Date :

Sep 1, 2013

Anticipated Study Completion Date :

Sep 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
NEUROSTEM®-AD A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain	Biological: NEUROSTEM®-AD NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed. Other Names: human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs)
Control Group A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows: Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia. For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study.

Arm

Intervention/Treatment

NEUROSTEM®-AD

A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain

Biological: NEUROSTEM®-AD

NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.

Other Names:

human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs)

Control Group

A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows: Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia. For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study.

Outcome Measures

Primary Outcome Measures

Safety [upto 24 months post-op]
Incidence rate ot adverse events (vital signs, physical examination, mixed lymphocyte reaction, and laboratory tests)

Secondary Outcome Measures

Efficacy [upto 24 months post-op]
Primary Efficacy Variable: ADAS-cog response rate, ADAS-cog response is defined as when ADAS-cog score at the end of the study is not worse than the Baseline score. Secondary Efficacy Variables: Changes in Seoul Instrumental Activities of Daily Living (S-IADL) Changes in Mini Mental State Examination Korean verson (K-MMSE) Changes in Caregiver-administered Neuropsuchiatric Inventory Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Changes in CMRglc: regional cerebral metabolic rate for glucose (FDG-PET)

Eligibility Criteria

Criteria

Ages Eligible for Study:

50 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

TEST GROUP

Inclusion Criteria:

Subjects who have enrolled and completed the Phase I cliical trial: The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease
Subjects who are willing to participate in the study and sign the consent form

Exclusion Criteria:

Females who are pregnant or nursing
Subjects who have participated in another clinical study within the 3 months prior to the initiation of this study
Subjects who are restricted from undergoing exams perfomed during the study (i.e. MRI, CT, or PET screening)
Subjects who the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above

CONTROL GROUP

Inclusion Criteria:

Patients with a moderate alzheimer's disease, diagnosed with a dementia of alzheimer's type, according to the DSM-VI and NINCDS-ADRDA criteria, and shows amyloid-positive in a PIB-PET

Exclusion Criteria:

Subjects with a psychological disease (i.e. depression, schizophrenia, bipolar disorder, etc)
Subjects with a dementia caused by other degenerative neurological diseases (infection of the CNS, such as HIV or Syphilis), head trauma, Creutzfeld-Jacob disease, Pick's disease, Huntington's disease, and Parkinson's disease)
Subjects with a vascular dementia as determined by the clinical criteria of DSM IV and the imaging criteria of Erkinjuntii
Subjects with severe white matter hyperintensities (WMH); Severe WMH is defined as, according to Clinical Research Center for Dementia of South Korea, a condition in which the deep white matter is 25 mm or greater and the periventricular capping/banding is 10 mm or greater in lengths.
Subjects with a history of stroke within the 3 months prior to the study enrollment
Subjects with a severe liver disease (ALT/AST values are higher than twice the normal range)
Subjects with a severe renal disease (1.5mg/dL or more of serum creatinine)
Pregnant or lactating women
Subjects with abnormal findings of the clinical laboratory values at Visit 1:
Hemoglobin < 9.5g/dL in male < 9.0 g/dL in female
Total WBC count < 3000/mm3
Total bilirubin ≥ 3 mg/dL
Subjects with a suspected active lung disease, based on the chest X-ray result at Visit 1
Females of childbearing age who does not practice medically acceptable method of contraception during the study
Subjects who have previously failed Screening for participation in this study
Subjects who have participated in another clinical study within the 3 months prior to the initiation of this study
Subjects with a bleeding disorder (platelet count < 150,000/mm3; PT ≥ 1.5; INR or aPTT ≥ 1.5 X control
Subjects with a cancer (including brain tumor)
Subjects with a history of alcohol or drug abuse
Subjects who are restricted from undergoing exams perfomed during the study (i.e. MRI, CT, or PET screening)
Patients who the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above